Post-COVID, Centene Foresees Expansion in MA and Medicaid

Providing updated guidance three months into the COVID-19 pandemic, managed Medicaid leader Centene Corp. last month raised its full year adjusted earnings per share outlook by 20 cents at the midpoint to an EPS range of $4.76 to $4.96. And while only an estimated 7% of 2019 revenue came from Medicare, executives recently emphasized Centene’s expectation that the Medicare market will be a growth driver going forward.

During its 2020 Virtual Investor Day on June 12, the insurer said it expects total revenues for full year 2020 to be between $109.5 billion and $111.9 billion. That’s a reduction of $500 million due to the delayed start date of its North Carolina Medicaid pact. Centene also said it expects overall membership growth to peak in the third quarter with an increase of approximately 1.9 million members, driven in large part by Medicaid. Centene as of March 31 served 23.8 million enrollees, including 11.8 million Medicaid lives. The acquisition of WellCare Health Plans, Inc., which closed in January, roughly doubled Centene’s Medicare Advantage membership to 976,700 lives. WellCare also had 4.4 million stand-alone Prescription Drug Plan members as of March 31.

© 2024 MMIT
Lauren Flynn Kelly

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues, including drug benefits and specialty pharmacy, for more than a decade. She served as editor of Drug Benefit News (the predecessor to Radar on Drug Benefits) from 2004 to 2005 and again from 2011 to 2016, and now manages Radar on Medicare Advantage. Lauren graduated from Vassar College with a B.A. in English.

Related Posts

achp-logo
April 18

ACHP: Final Rule Checks ‘Untethered’ Agent, Broker Fees Impacting Competition

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
April 18

News Briefs: UnitedHealth Reaffirms Full-Year Earnings Guidance Despite Cyberattack Impact

READ MORE
older-black-man
April 18

How Does MA Plan Design Impact Enrollment, Equity?

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today